Market Highlights:
Cardiac tamponade, is the build-up of fluid in the sac
around the heart (pericardium) resulting in pressure and difficulty in
compression of the heart. Difficulty in compression of the heart results in
reduced blood volume to be pumped by the heart. The symptoms of cardiac
tamponade include shortness of breath, weakness, light-headedness, cough,
fatigue, swelling of the abdomen, veins in the arms or legs, or other areas,
pale skin, or skin that is blue- or gray-tinted, rapid heartbeat, anxiety or
restlessness, fainting etc. The causes of cardiac tamponade are cancer, kidney
failure, chest trauma, and pericarditis, connective tissue diseases,
hypothyroidism, aortic rupture, following cardiac surgery, tuberculosis etc.
Cardiac tamponade can be life-threatening if not treated. Risk factors which
increases the chances of cardiac tamponade include heart surgery, heart attack,
injury to the heart, end-stage lung cancer, radiation therapy to the chest,
hypothyroidism, systemic lupus erythematosus etc.
The diagnosis segment of cardiac tamponade especially the
non-invasive Magnetic Resonance Imaging (MRI) is growing fast. Magnetic
Resonance Imaging (MRI) is the diagnostic test of choice. The surgery segment
is led by pericardiocentesis which involves drainage of the fluid by use of a
needle. Cardiac tamponade has a frequency of approximately 2 per 10,000 per
year in the US.
The market drivers for cardiac tamponade market are
increasing cardiac cases such as heart attack, other factors includes cancer,
kidney failure, end-stage lung cancer, hypothyroidism, rising screening and
penetration of healthcare, growing awareness about cardiac diseases and growing
income and healthcare expenditure etc. The market restraints are cost of
cardiac tamponade surgery, complications and risk of the surgery, invasive
nature of treatment etc.
Global Cardiac tamponade Market Players
Key players profiled in the report are Boston Scientific
Corporation, Medtronic, Inc., St. Jude Medical Inc., Hitachi, Ltd., Koninklijke
Philips N.V., Siemens Healthcare Private Limited, and Toshiba Medical Systems
Corporation, General Electric Company, and others.
Regional Analysis
The Americas accounts for a significant market share owing
to extensive use of medications and high expenditure on the health care.
Additionally, the fastest uptake of new drugs in the US drives the cardiac
tamponade market. Also, concentration of major research companies in the
developed countries of this region is adding fuel to the market growth. The
large US expenditure on healthcare accounting to 16% of GDP also cruises the
sale of cardiac tamponade treatment. The large number of specialized cardiac
centres in the US also drives the market.
Europe is the second largest market in the world due to high
income and healthcare penetration. Europe is led by nations such as Germany and
France. UK is expected to be the fastest growing market.
Asia Pacific region is expected to grow rapidly and China
and India are likely to lead this market due to fast growing healthcare sector
during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are estimated
to drive the Middle East & African market. The development of large
hospitals such as the King Fahd hospital in Riyadh is driving the market. The
African region is expected to witness a moderate growth owing to poor economic
and political conditions and poor healthcare development.
Taste the market data and market information presented
through more than 50 market data tables and figures spread over 80 pages of the
project report. Avail the in-depth table of content (TOC) & market synopsis
on “Global Cardiac tamponade Market” Research Report – Forecast till 2023.
Segmentation
The global cardiac tamponade market has been segmented on
the basis of diagnosis, treatment, and end user.
Based on diagnosis, the market has been segmented as X-ray,
Computed Tomography (CT), Magnetic Resonance Imaging (MRI), coronary
angiography, electrocardiogram (EKG), and others.
Based on treatment, the market has been segmented as surgery
and drugs. The surgery segment has been sub-segmented as pericardiocentesis,
thoracotomy and others. The drugs segment has been sub-segmented as
antibiotics, blood volume expanders and others.
Based on the end user, the market has been segmented as
hospitals & clinics, academic and research and others.
No comments:
Post a Comment